







Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-
risk patients following a myocardial infarction. European Journal of 
Heart Failure, 22(5), pp. 848-855. 
 
 
There may be differences between this version and the published 
version. You are advised to consult the publisher’s version if you wish 
to cite from it.  
 
This is the peer reviewed version of the following article: 
 
 
Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-
risk patients following a myocardial infarction. European Journal of 
Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) 
 
This article may be used for non-commercial purposes in accordance 






     
 
 







Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk/    
 1 
Title:   Predictors of sudden cardiac death in high risk patients 
following a myocardial infarction 
 
Authors:   Kieran F. Docherty MBChB
1 
  
    João Pedro Ferreira MD, PhD
2,3 
    
Abhinav Sharma MD
4 
    Nicolas Girerd MD, PhD
2 





    Mark C. Petrie MBChB
1 
    Pardeep S. Jhund MBChB, PhD
1 
Kenneth Dickstein MD, PhD
6 
    Marc A. Pfeffer MD, PhD
7 
    Bertram Pitt MD
8 




    Faiez Zannad MD, PhD
2 






BHF Cardiovascular Research Centre, University of Glasgow, 
Glasgow, Scotland, UK 
 
2
 Université de Lorraine INSERM, Centre, d'Investigations 
Cliniques Plurithématique 1433, INSERM U1116, CHRU de 
Nancy, F-CRIN INI-CRCT, France 
 3
 Department of Physiology and Cardiothoracic Surgery, 
Cardiovascular Research and Development Unit, Faculty of 
Medicine, University of Porto, Portugal 
 4
 Division of Cardiology, McGill University Health Centre 
(Montreal, Quebec, Canada) 
 2 
5
Department of Medical Statistics, London School of Hygiene 
& Tropical Medicine, London, UK 
 
6
 Department of Cardiology, University of Bergan, Stavanger 
University Hospital, Stavanger, Norway. 
 
7
 Division of Cardiovascular Medicine, Brigham & Women's 
Hospital, Harvard Medical School, Boston, Massachusetts. 
8
 Department of Medicine, University of Michigan School of 
Medicine, Ann Arbor, Michigan. 
 
Correspondence: Prof. John J. V. McMurray 
 Institute of Cardiovascular and Medical Sciences 
 BHF Glasgow Cardiovascular Research Centre 
 University of Glasgow 
 Glasgow, G12 8TA 
 United Kingdom 
 Email:  john.mcmurray@glasgow.ac.uk 
 Tel: +44 141 330 3479       
 Fax: +44 141 330 6955 
 
Word count  Abstract: 235 words 
 Text: 3225 words 
 
 









To develop a risk model for sudden cardiac death (SCD) in high-risk acute myocardial 
infarction (AMI) survivors. 
 
Methods and Results 
Data from the Effect of Carvedilol on Outcome After MI in Patients With Left Ventricular 
Dysfunction trial (CAPRICORN) and the Valsartan in Acute MI Trial (VALIANT) were 
used to create a SCD risk model (with non-SCD as a competing-risk) in 13202 patients. The 
risk model was validated in the Eplerenone Post–Acute MI Heart Failure Efficacy and 
Survival Study (EPHESUS). 
 
The rate of SCD was 3.3 (95%CI 3.0-3.5) per 100 person-years over a median follow-up of 
2.0 years. Independent predictors of SCD included age >70 years; heart rate ≥70 bpm; 
smoking; Killip class III/IV; left ventricular ejection fraction (LVEF) ≤30%; atrial 
fibrillation; history of prior MI, heart failure or diabetes; estimated glomerular filtration rate 
<60ml/min/1.73m
2
; and no coronary reperfusion or revascularisation therapy for index AMI. 
The model was well calibrated and showed good discrimination (C-statistic = 0.72), 
including in the early period after AMI. The observed 2-year event rates increased steeply 





An easy to use SCD risk score developed from routinely collected clinical variables in 
patients with heart failure, left ventricular systolic dysfunction or both, early after AMI was 
superior to LVEF. This score might be useful in identifying patients for future trials testing 
treatments to prevent SCD early after AMI. 
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Early reperfusion in patients with acute myocardial infarction (AMI) has greatly reduced 2 
short-term case-fatality.
1
 However, the survivors remain at risk of sudden cardiac death 3 
(SCD) over the subsequent weeks, months and years, despite secondary preventive 4 
pharmacotherapy with beta-blockers, antiplatelet therapy, statins, angiotensin converting 5 
enzyme inhibitors/angiotensin receptor blockers and mineralocorticoid receptor antagonists. 6 
Indeed, SCD accounts for between 20-40% of all deaths after discharge and the risk is 7 
especially high in the first year after AMI.
2,3
 For example, a post-hoc analysis of the 8 
Valsartan in Acute Myocardial Infarction Trial (VALIANT) reported that the risk of SCD 9 
was 10-fold higher in the 30 days following AMI than later, falling from 1.4 percent per 10 
month to 0.14 percent per month after 2 years in patients with heart failure (HF), left 11 
ventricular systolic dysfunction (LVSD), or both, complicating their index event.
4
 Therefore, 12 
the identification and treatment of patients at high-risk of SCD after AMI remains a clinical 13 
priority.  14 
 15 
Current guidelines advocate the use of an implantable cardioverter defibrillator (ICD) for 16 
primary prevention of sudden cardiac death (SCD) in individuals with a left ventricular 17 
ejection fraction (LVEF) that remains reduced  (≤35%) more than 40 days after AMI, despite 18 
optimized, evidence-based, medical therapy (90 days or more in patients who undergo 19 
myocardial revascularization).
5,6
 Conversely, implantation of a device before 40 days is not 20 
recommended because two randomised controlled trials failed to show any benefit of an ICD 21 
during that early period in patients with a depressed LVEF and markers of impaired 22 
autonomic function (elevated heart rate, depressed heart-rate variability or non-sustained 23 
ventricular tachycardia).
7,8
 More recently, a third trial showed no benefit of a wearable 24 




 Nevertheless, the question remains whether selected individuals at particularly high 26 
risk of SCD can be identified, as they might still benefit from more targeted use of an ICD 27 
early after AMI. 28 
 29 
The aims of this study were to characterise patients who experienced SCD after AMI and 30 
develop a calibrated and validated risk score for SCD using routinely collected clinical 31 



















The high-risk AMI initiative was a collaborative undertaking by the chairpersons of the 50 
steering committees of 4 randomized controlled trials to provide a large, comprehensive and 51 
statistically robust dataset to help further understanding of outcomes in high-risk survivors of 52 
AMI.
10
 The dataset was composed of the following trials: the Effect of Carvedilol on 53 
Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction 54 
(CAPRICORN) trial
11,12
; the Eplerenone Post–Acute Myocardial Infarction Heart Failure 55 
Efficacy and Survival Study (EPHESUS)
13,14
; the Optimal Trial in Myocardial Infarction 56 
With Angiotensin II Antagonist Losartan (OPTIMAAL)
15,16
; and the Valsartan in Acute 57 
Myocardial Infarction Trial (VALIANT).
17,18
 OPTIMAAL was excluded from the present 58 
analysis because data on LVEF were not collected. The three remaining trials, CAPRICORN, 59 
EPHESUS and VALIANT enrolled patients with left ventricular systolic dysfunction, heart 60 
failure, or both, between 12 hours and 21 days following an AMI. The full details of the 61 
enrolled patients, the inclusion and exclusion criteria and the results for each individual trial 62 
are published.
12,14,18
 The pooled dataset did not include information regarding the randomised 63 
treatment allocations for each trial.
10
 All trials were conducted in accordance with the 64 
Declaration of Helsinki and were approved by ethics committees. All participants gave 65 
written informed consent to participate in the trials. 66 
 67 
Outcomes 68 
The primary outcome of interest in this study was SCD. The definitions for SCD used in each 69 
individual trial are detailed in Supplementary Table 1. Mortality due to causes other than 70 
SCD was considered the competing risk event.   71 
 8 
Statistical methods 72 
Continuous variables are expressed as means    standard deviations and categorical variables 73 
as frequencies and percentages. Differences in baseline characteristics according to the 74 
occurrence or not of SCD were assessed using the Student’s t-test and the chi-square test for 75 
continuous and categorical variables, respectively.  76 
 77 
Time-to-event analysis was conducted using a competing risk model as described by Fine and 78 
Gray with SCD as outcome event and mortality due to any other cause as a competing risk.
19
 79 
Time-to-event was calculated as time from randomization, as time from AMI to 80 
randomization was not available for all patients. Log-linearity was checked by plotting the 81 
beta estimates versus the mean across deciles and then clinically relevant cutoffs were chosen 82 
for the candidate variables. Variables were entered in the multivariable model in a backward 83 
stepwise regression analysis with the p value to enter and stay in the model set to p≤0.1 and 84 
p<0.05, respectively. Variables considered to be of potential prognostic import were age, sex, 85 
body mass index, systolic blood pressure, heart rate, LVEF, Killip class, estimated 86 
glomerular filtration rate (eGFR, calculated using the Chronic Kidney Disease Epidemiology 87 
Collaboration formula), previous MI, history of HF prior to randomization, atrial fibrillation 88 
(AF), peripheral artery disease, hypertension, diabetes mellitus, previous stroke, reperfusion 89 
or revascularization therapy for index MI. Use of beta-blockers and MRA were not included 90 
for consideration in the model as information on randomized treatment allocation was not 91 
available in the HRMI dataset. Sodium, potassium, and anaemia (defined as haemoglobin 92 
<13 g/dL or 12 g/dL for men and women, respectively) were not included in the models due 93 
to high proportion of missing values (>80%). Patients with missing LVEF measurements 94 
were excluded from the models (15%).  Multiple imputation for missing values was not 95 
 9 
performed. Patients with an ICD at baseline (n=96; 0.3%) were excluded for the purposes of 96 
these analyses.  97 
 98 
The competing risk regression model was derived from a cohort of patients from the 99 
VALIANT and CAPRICORN trials. Model discrimination was determined by calculation of 100 
the C- statistic and the Hosmer-Lemeshow test. Assessment of model calibration was 101 
performed by plotting the cumulative incidence of observed versus expected SCD events 102 
derived from the competing risk model across quintiles of the predicted risk. The ability of 103 
the model to reclassify events compared to the use of LVEF ≥35% alone was assessed with a 104 
10-fold cross-validation with 1000x bootstrap net reclassification improvement (NRI) and 105 
integrated discrimination improvement (IDI) statistics for the outcome of SCD. External 106 
validation of the model was performed in the EPHESUS trial cohort. 107 
 108 
A simple, easy-to-use integer risk score was created with integer points assigned to each 109 
prognostic variable in the model based on the log-hazard ratio estimates. For continuous 110 
variables included in the model, clinically relevant cut-offs were used to create either 2 or 3 111 
groups.  The risk score for each patient was calculated by totalling the points across all 112 
chosen prognostic variables. From the overall distribution of the risk score we formed 5 113 
categories of risk. Within each risk score category, we calculated the number of events and 114 
the cumulative event incidence at 40 days, 90 days, 1 years, and 2 years. Kaplan-Meier plots 115 
were drawn showing the cumulative incidence curves by risk category. After fitting the 116 
competing risk regression model, we assessed time interaction using log[−log(survival)] 117 
curves for each category of risk versus ln(time). The plotted lines were reasonably parallel, 118 
 10 
meaning that the proportional-hazards assumption had not been violated (proportional-119 
hazards Schoenfeld residuals by risk score quintiles, p=0.86 [Supplementary Figure 1]).  120 
 121 
All analysis was performed with STATA software version 15 (StataCorp, College Station, 122 
Texas). All p-values are two-sided and a p-value <0.05 was considered statistically 123 
significant. 124 
 125 
  126 
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RESULTS 127 
Baseline characteristics 128 
The derivation cohort included 13202 patients from VALIANT and CAPRICORN. The 129 
external validation cohort comprised 6632 patients from EPHESUS. The baseline 130 
characteristics of the patients of the derivation and validation cohorts are shown in Table 1 131 
and Supplementary Table 2, respectively. 132 
 133 
In the derivation cohort, the mean age was 64.1  11.8 years and 29.8% were female. There 134 
were 2390 (18.1%) deaths during a median follow-up of 2.0 years (interquartile range: 1.5-135 
2.5 years), of which 818 (34.2%) were due to SCD. The overall incidence rate of SCD was 136 
3.3 (95% confidence interval [C.I.] 3.0-3.5) per 100 patient years. 137 
 138 
Compared to patients alive at end of follow-up, those who experienced SCD were older, 139 
more often female, more commonly had a history of previous MI, atrial fibrillation, 140 
peripheral arterial disease, hypertension, diabetes, stroke and heart failure prior to 141 
randomization (Table 1). Body mass index and estimated glomerular filtration rate (eGFR) 142 
were lower, and systolic blood pressure and heart rate higher, in those experiencing SCD. 143 
Rates of coronary reperfusion or revascularization for the index AMI were lower in those 144 
with SCD compared to those surviving to end of follow-up. 145 
 146 
Risk Model 147 
The variables included in the final predictive model for SCD are detailed in Table 2. Age >70 148 
years, heart rate ≥70 beats per minute, active smoking, Killip class III/IV, LVEF ≤30%, atrial 149 
 12 
fibrillation, history of prior MI, heart failure or diabetes mellitus, eGFR <60ml/min/1.73m
2
 150 
and no reperfusion or revascularisation for the index AMI were independently associated 151 
with a higher risk of SCD. The risk score derived from these predictive variables ranged from 152 
0 to 14 points (Table 2). 153 
 154 
The final model was well calibrated with a steep gradient in risk observed when plotted by 155 
quintiles of predicted risk (Figure 1). The model discrimination was good with a C-statistic of 156 
0.72 and the Hosmer-Lemeshow goodness-of-fit test gave a p-value of 0.33 supporting the 157 
good calibration of the model. When externally validated in EPHESUS, the model retained 158 
good calibration with good discrimination (C-statistic=0.70 [Supplementary Table 3]). 159 
Patient characteristics were similar between the derivation and validation cohort 160 
(Supplementary Table 4).  161 
 162 
Risk Model compared with LVEF ≤35% alone 163 
To compare the derived risk score with what is recommended in current guidelines, we also 164 
calculated the C-statistic using LVEF 35% as the sole predictor variable in a competing risk 165 
model. An LVEF of 35% alone was a poor discriminator of the risk of SCD with a C-166 
statistic of 0.54. The addition of the variables identified in the risk model, greatly improved 167 
the reclassification of the SCD events compared to an LVEF 35% alone, with a continuous 168 





Event Rates 173 






 year 174 
following AMI was 4.8% (95% CI: 4.4-5.2), 2.0% (95% CI: 1.7-2.3), and 1.5% (95% CI: 1.2-175 
2.0), respectively.  176 
 177 
The observed two-year incidence of SCD increased from 1.9% in the lowest to 13.4% in the 178 
highest quintile of risk score, respectively. This was consistent with the predicted event rates 179 
(Table 2). An online calculator {LINK to supplement excel file} is provided for calculation 180 
of the risk of SCD in patients with heart failure, left ventricular systolic dysfunction or both 181 
after AMI. 182 
 183 
To further explore the performance of the model in the period immediately following AMI, 184 
we calculated the predicted rates of SCD at 40 and 90 days after randomization and found 185 
these to calibrate well against the observed rates with moderate/good discrimination and a C-186 










In this post-hoc analysis of the high-risk AMI database, we identified eleven routinely 196 
collected clinical variables which were independent predictors of SCD. Importantly, our 197 
model accounted for the competing risk of non-sudden death. Using the eleven variables 198 
identified, we created a simple risk score which performed well (C-statistic=0.72), both early 199 
and later after AMI. By contrast, we found that a LVEF of ≤35%, by itself, was a poor 200 
predictor of the risk of SCD (C-statistic=0.54).  201 
 202 
The latter finding is consistent with the evidence from three trials showing no benefit from an 203 
implanted or wearable defibrillator in patients with a low LVEF early after AMI.
7–9
 Yet, 204 
arguably, it is in the early period after AMI that interventions to reduce the risk of SCD are 205 
needed most. This is because proximity to the acute coronary event is also an important 206 
predictor of the risk of SCD. For example, in VALIANT, the rate of SCD was higher during 207 
the first 30 days after AMI in patients with a LVEF >40% than in those more than 90 days 208 
after AMI with a LVEF ≤30%.
4
  Collectively, these findings highlight the need to identify 209 
variables, other than LVEF, which will improve SCD risk stratification early after AMI. Such 210 
a strategy could allow better targeting of defibrillators (or other treatments) to the patients 211 
most likely to benefit from them. The risk score described here may offer that possibility.  212 
 213 
However, a first step is to consider whether the variables in the score proposed are 214 
biologically plausible. The independent predictors of SCD we identified included absence of 215 
coronary reperfusion, prior myocardial infarction and history of heart failure. Together these 216 
are clearly related to the development of myocardial scar and left ventricular systolic 217 
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dysfunction, as well as myocardial ischaemia, each of which is a powerful substrate for 218 
ventricular arrhythmias; each also interacts with the others to amplify risk.  219 
 220 
We also found that renal dysfunction and diabetes mellitus were associated with a higher risk 221 
of SCD. This was also unsurprising, given that both these conditions increase the risk of all 222 
the substrates for electrical instability described above.
20–22
 Moreover, renal dysfunction and 223 
diabetes each reduce the potential protection offered by coronary revascularisation as both 224 
conditions are associated with a diffuse coronary artery disease phenotype and a lower 225 
probability of successful percutaneous and surgical revascularisation.
23
 Each of renal 226 
dysfunction and diabetes also increases the risk of developing heart failure after AMI, a 227 
further way in which they likely augment the risk of SCD.
24,25
 Autonomic dysfunction is also 228 
a recognised complication of diabetes, itself increasing the risk of cardiac electrical 229 
instability. Both renal dysfunction and diabetes cause electrolyte abnormalities, particularly 230 
hyperkalaemia, which may also potentiate the risk of arrhythmias.  The risks of heart failure, 231 
diabetes, renal impairment and more extensive coronary disease are also associated with 232 
more advanced age (and older individuals are less likely to undergo coronary reperfusion and 233 
revascularisation). 234 
 235 
Another predictor of SCD was elevated heart rate, which may be a marker of autonomic 236 
instability.
26
 Smoking at the time of index AMI was also associated with risk of SCD, 237 
possibly because of the risk of further coronary events and earlier failure of coronary 238 
revascularisation in patients who continue to smoke.
27
  239 
 240 
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Even if biologically plausible, any risk score of this type must also identify a relatively small 241 
and high-risk group of patients, to make any intervention based on it potentially cost-242 
effective. How discriminating might our risk score be in clinical practice? Robust 243 
epidemiological data demonstrate that no more than one-third of patients with AMI develop 244 
heart failure, left ventricular systolic dysfunction or both within 3 months of their event i.e. 245 
the denominator for use of this risk score is no more than a third of all patients with AMI.
28
 If 246 
only patients with a risk score in the top two quintiles are considered further, just one third of 247 
the initial patients (i.e. 10% of all patients with AMI) would be considered at sufficiently 248 
high risk of SCD to potentially merit further intervention.  Specifically, in the derivation 249 
cohort, the risk of SCD in these individuals was 8.2% at 90-days and 22.4% at 2-years i.e. an 250 
approximately 1-in-12 patients experienced SCD at 90-days and 1-in-5 at 2 years. Targeted 251 
defibrillator (or other) therapy should be feasible and potentially cost-effective in such an 252 
enriched subgroup of AMI survivors. 253 
 254 
Of course, the key question is whether a score like the one proposed identifies patients with a 255 
modifiable risk of SCD.  The only way to test this is to conduct an intervention trial. 256 
However, if such a trial were based on the score we propose, it would require a considerable 257 
divergence form conventional thinking about primary prevention of SCD. This is because 258 
40% of the patients in highest two quintiles of risk-score had a baseline LVEF >30%, yet 259 
current guidelines for use of defibrillators is focussed on patients with a low LVEF.
5,6
  260 
 261 
It might also be possible to improve upon our score and to consider alternative interventions 262 
to a defibrillator. The addition of neprilysin inhibition to renin-angiotensin system blockade 263 




 The potential benefits of this pharmacological approach in patients with 265 
LVSD, heart failure, or both following AMI is currently being examined in the PARADISE-266 
MI trial (ClinicalTrials.gov identifier NCT02924727). The burden of ventricular scar and 267 
replacement fibrosis, detected by cardiac magnetic resonance imaging, is associated with the 268 
risk of ventricular arrhythmias in patients with heart failure and other cardiomyopathies, and 269 
may help identify individuals, irrespective of LVEF, who are at increased risk of SCD.  270 
 271 
Limitations 272 
This was a post-hoc analysis and the patients analysed were selected through enrolment in 273 
clinical trials. Ideally, our score should be validated in a less selected population. The 274 
definition of SCD in each trial (Supplementary Table 1) and the maximum time from AMI 275 
from which randomization was permitted, differed somewhat. Furthermore, not all 276 
adjudicated sudden cardiac deaths represent events where a ventricular arrhythmia occurred 277 
and are potentially preventable by use of prophylactic defibrillators e.g. recurrent AMI, 278 
ventricular rupture or pulmonary embolism. Moreover, these other events should have 279 
reduced the predictive accuracy of the model yet it still performed well. To explore the 280 
potential for any bias due to these differences we calculated the C-statistic for each trial 281 
individually and found that the model performed equally as well in all three trials 282 
individually (CAPRICORN, 0.68 [95% CI 0.67-0.70]; VALIANT, 0.72 [0.71-0.74]; 283 
EPHESUS 0.70 [0.68-0.72]). Patients with multiple comorbidities may be at high risk of 284 
SCD but decision making regarding the appropriateness of therapies to prevent SCD such as 285 
ICD, should be made on a case by case basis and taking into account the degree of 286 
comorbidity and the competing risk of non-SCD. Our risk score did not take account of how 287 
variables changed over time after AMI. Furthermore, we were unable to account for the use 288 
of implantable cardioverter defibrillators following randomisation, a factor which may 289 
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modify the subsequent risk of SCD. Some potentially relevant variables (e.g. potassium) were 290 
not available. A further limitation is that information regarding treatment with renin-291 
angiotensin aldosterone system inhibitors and beta-blockers was not available therefore the 292 
risk model does not take into account those patients who did not receive these treatments 293 
known to reduce the risk of SCD. The variables considered for inclusion in the risk model are 294 
routinely collected in clinical with the aim of making the risk score easy to calculate. This 295 
approach may ignore other variables which are potentially associated with the risk of SCD 296 
e.g. burden of myocardial scar and markers of impaired autonomic function.   The trials 297 
providing the data used in the analysis are over 15 years old and may not therefore, represent 298 
contemporary clinical practice; in particular, increased use of primary reperfusion therapy 299 
may mean that modern rates of SCD are lower than those presented. We used classical 300 
methods of risk modelling but it may be that more complex, and potentially more accurate, 301 
models could be constructed by using machine learning approaches and may be an area for 302 
further research.
30
 The proposed use of this score, to target interventions to reduce the risk of 303 
sudden death, needs to be tested in a prospective randomized controlled trial.  304 
 305 
Summary 306 
We developed an easy to use score for predicting the risk of SCD in patients with heart 307 
failure, left ventricular systolic dysfunction or both, early after AMI.  The score uses 308 
routinely collected clinical variables and is superior to (and additive to) LVEF on its own. 309 
This score might be useful in identifying patients for future trials testing treatments aimed at 310 
reducing the risk of SCD early after AMI. 311 
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Figure 1: Model calibration plot: percentage of observed versus predicted risk of sudden 
cardiac death at 2-years according to quintile of risk score 
 
Legend: SCD, sudden cardiac death. Note: The models were also well calibrated in the 
validation set: a steep gradient in risk by quintiles of predicted risk was observed (Table 2). 
 





















Table 1: Baseline characteristics of the study population (derivation set: CAPRICORN and 
VALIANT) 
 
Table 2: Multivariable competing risk model for sudden cardiac death (derivation set: 
CAPRICORN and VALIANT) 
 
Table 3: Cumulative incidence of sudden cardiac death at 2-years by quintile of risk score 































Age (years) 62.9±11.7 66.9±11.2 70.5±10.5 <0.001 
Age (years)     
≤60 4418 (40.9%) 225 (27.5%) 265 (16.9%) <0.001 
61-70 3241 (30.0%) 237 (29.0%) 410 (26.1%) 
 >70 3153 (29.2%) 356 (43.5%) 897 (57.1%) 
 Male  7738 (71.6%) 556 (68.0%) 977 (62.2%) <0.001 
BMI ≥25 kg/m² 7630 (72.1%) 542 (67.8%) 973 (64.4%) <0.001 
Current smoking 3642 (33.7%) 255 (31.2%) 367 (23.5%) <0.001 
SBP ≥140 mmHg 1843 (17.1%) 182 (22.4%) 290 (18.5%) <0.001 
Heart rate ≥70 bpm 7448 (69.3%) 605 (74.5%) 1207 (77.2%) <0.001 
LVEF (%) 35.5±9.8 32.0±9.8 32.7±10.0 <0.001 
LVEF ≤30% 3332 (30.8%) 389 (47.6%) 733 (46.6%) <0.001 
Killip III/IV 1749 (16.2%) 220 (26.9%) 499 (31.8%) <0.001 
eGFR (ml/min/1.73m2)     
≤45 1209 (11.3%) 171 (21.3%) 477 (30.6%) <0.001 
46-60 2282 (21.4%) 227 (28.2%) 420 (27.0%) 
 >60 7192 (67.3%) 406 (50.5%) 661 (42.4%) 
 Sodium ≤135 mmol/L 215 (13.8%) 15 (14.3%) 24 (18.0%) 0.41 
Potassium (mmol/L),     
<4 134 (8.7%) 11 (10.5%) 12 (9.0%) 0.30 
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4-5 1169 (75.5%) 70 (66.7%) 96 (72.2%)  
>5 246 (15.9%) 24 (22.9%) 25 (18.8%) 
 Previous MI  2700 (25.0%) 366 (44.7%) 685 (43.6%) <0.001 
HF history  1055 (9.8%) 202 (24.7%) 390 (24.8%) <0.001 
Atrial fibrillation history 1224 (11.3%) 176 (21.5%) 350 (22.3%) <0.001 
PAD history 795 (7.4%) 92 (11.3%) 226 (14.4%) <0.001 
Hypertension history 6075 (56.2%) 530 (64.8%) 1016 (64.6%) <0.001 
Diabetes history 2571 (23.8%) 265 (32.4%) 583 (37.1%) <0.001 
Stroke history 729 (6.7%) 90 (11.0%) 204 (13.0%) <0.001 
Anaemia 397 (25.9%) 47 (45.6%) 49 (36.6%) <0.001 
Reperfusion during index 
event 6021 (55.7%) 274 (33.5%) 582 (37.0%) <0.001 
 
Legend: BMI, body mass index; SBP, systolic blood pressure; LVEF, left ventricular ejection 
fraction; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; HF, heart 






Table 2: Multivariate competing risk model for sudden cardiac death (derivation set: 
CAPRICORN and VALIANT) 
 
Retained variable HR (95%CI) Coefficient P-value Integer 
Age >70 years 1.24 (1.02-1.51) 0.22 0.030 +1 
Heart rate ≥70 bpm 1.18 (1.01-1.39) 0.17 0.038 +1 
Smoking (active) 1.32 (1.10-1.58) 0.28 0.003 +1 
Killip III/IV 1.20 (1.02-1.42) 0.19 0.027 +1 
LVEF ≤30% 1.55 (1.34-1.79) 0.44 <0.001 +2 
Previous MI 1.53 (1.31-1.79) 0.43 <0.001 +2 
Atrial fibrillation 1.45 (1.22-1.73) 0.37 <0.001 +1 
HF history 1.36 (1.14-1.63) 0.31 0.001 +1 
Diabetes 1.19 (1.02-1.38) 0.17 0.026 +1 
eGFR <60 ml/min/1.73m
2
 1.36 (1.16-1.59) 0.31 <0.001 +1 
No index reperfusion 1.87 (1.60-2.18) 0.62 <0.001 +2 
 
C-index full model=0.72 (95% CI:0.71-0.74) 
C-index LVEF alone=0.54 (95% CI:0.53-0.55) 











Baseline, n Censored before 
40 days, n 
Non-SCD at  
40 days, n 
SCD at  
40 days, n 
SCD observed cumulative 
incidence at 40 days, %  
SCD predicted 
cumulative incidence at 
40 days, % 
1 (0-2 points) 2808 3 20 13 0.5 0.4 
2 (3-4 points) 3940 5 84 26 0.7 0.7 
3 (5 points) 1712 2 54 16 0.9 1.1 
4 (6-7 points) 2736 3 104 54 2.0 1.8 
5 (8-14 points) 1764 2 120 60 3.4 3.5 
Risk score 
quintiles 
Baseline, n Censored before 
90 days, n 
Non-SCD at  
90 days, n 
SCD at  
90 days, n 
SCD observed cumulative 
incidence at 90 days, %  
SCD predicted 
cumulative incidence at 
90 days, % 
1 (0-2 points) 2808 4 26 19 0.7 0.7 
2 (3-4 points) 3940 10 109 43 1.1 1.3 
3 (5 points) 1712 5 71 36 2.1 1.9 
4 (6-7 points) 2736 6 158 84 3.1 2.8 




Baseline, n Censored before  
1 year, n 
Non-SCD at  
1 year, n 
SCD at  
1 year, n 
SCD observed cumulative 
incidence at 1 year, %  
SCD predicted 
cumulative incidence at 1 
year, % 
1 (0-2 points) 2808 111 50 37 1.3 1.6 
2 (3-4 points) 3940 163 177 105 2.7 2.8 
3 (5 points) 1712 70 131 78 4.6 4.1 
4 (6-7 points) 2736 112 304 169 6.2 5.8 
5 (8-14 points) 1764 38 319 174 9.9 10.5 
Risk score 
quintiles 
Baseline, n Censored before  
2 years, n 
Non-SCD at 2 
 years, n 
SCD at  
2 years, n 
SCD observed cumulative 
incidence at 2 years, %  
SCD predicted 
cumulative incidence at 2 
years, % 
1 (0-2 points) 2808 1023 75 50 1.9 2.3 
2 (3-4 points) 3940 1520 255 135 3.6 4.0 
3 (5 points) 1712 599 179 101 6.2 5.6 
4 (6-7 points) 2736 879 432 232 9.0 8.0 
5 (8-14 points) 1764 432 459 229 13.4 14.4 
 
Abbreviations as per Table 1
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Figure 1: Model calibration plot: percentage of observed versus predicted risk of 




Note: The models were also well calibrated in the validation set: a steep gradient in risk by 








Figure 2: Kaplan-Meier failure cumulative incidence curve by quintile of risk score  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
